INOVIO’s ASCO and ASGCT updates may sharpen scrutiny of its DNA medicine strategy
INOVIO has a regulatory clock ticking. New INO-3107 and hemophilia A data may show whether its DNA platform can move beyond promise.
Pharma & Biotech
Pharma & Biotech
What the Akeso–INOVIO immunotherapy collaboration signals for the future of glioblastoma clinical research
Akeso and INOVIO test cadonilimab plus INO-5412 in the INSIGhT glioblastoma trial. Explore what this immunotherapy strategy could mean for GBM research.
Medical Devices & Diagnostics
PharmaJet’s needle-free system to power Scancell’s melanoma Phase 3 after strong DNA therapy data
PharmaJet’s needle-free device will deliver Scancell’s DNA immunotherapy in a Phase 3 melanoma trial. Find out what this means for the future of cancer vaccines.